Third Rock de­buts im­munome­tab­o­lism start­up Rheos with $60M launch round

Third Rock is push­ing one of its stealthy star­tups in­to the lime­light this morn­ing, with $60 mil­lion in fresh cap­i­tal and a plat­form tech that op­er­ates in the in­creas­ing­ly pop­u­lar field of im­munome­tab­o­lism.

The start­up, called Rheos Med­i­cines, has a drug dis­cov­ery tech that’s al­ready churned out two leads for the com­pa­ny that are both mov­ing in­to pre­clin­i­cal de­vel­op­ment.

Rheos, found­ed last sum­mer, is dig­ging in­to the new field of im­munome­tab­o­lism, which ba­si­cal­ly tries to un­der­stand — and lat­er har­ness — how a cell’s me­tab­o­lism af­fects dis­ease pro­gres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER